Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

04. Mai 2023 03:00 ET | Quelle: Endogena

Endogena Therapeutics Completes Enrollment Ahead of Schedule in its Phase 1/2a Trial of EA-2353 for Retinitis Pigmentosa

SAN FRANCISCO and TORONTO and ZÜRICH, Switzerland, May 04, 2023 (GLOBE NEWSWIRE) -- Endogena Therapeutics Inc., a clinical-stage biotech company, is pleased to announce that it has completed...
27. April 2023 12:23 ET | Quelle: The Rosen Law Firm PA

EQUITY ALERT: ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages Edgio, Inc. f/k/a Limelight Networks, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – EGIO, LLNW

NEW YORK, April 27, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Edgio,...
25. April 2023 06:00 ET | Quelle: Cabeau

Cabeau Commits to Plastic Neutrality and Debuts Sustainable Neck Pillow

LOS ANGELES, April 25, 2023 (GLOBE NEWSWIRE) -- In honor of Earth Month, global travel comfort brand Cabeau is proud to announce its plans and commitment to achieving plastic neutrality, along with...
12. April 2023 07:00 ET | Quelle: ONL Therapeutics

ONL Therapeutics Announces First Patient Dosed in Phase 2 Clinical Trial of First-in-Class Fas-Inhibitor in Patients with Macula-Off Rhegmatogenous Retinal Detachment

ANN ARBOR, Mich., April 12, 2023 (GLOBE NEWSWIRE) -- ONL Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal...
11. April 2023 07:00 ET | Quelle: ONL Therapeutics

ONL Therapeutics to Report Clinical Data on ONL1204 in Podium Presentation at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting

Presentation will review the results of ONL’s Phase 1 study of ONL1204 Ophthalmic Solution in patients with Macula-Off Rhegmatogenous Retinal Detachment Preclinical data in models of inherited...
10. April 2023 07:36 ET | Quelle: MAXIMIZE MARKET RESEARCH PRIVATE LIMITED

Vision Correction Market to reach USD 42.7 Mn by 2029 at a CAGR of 8.9 percent – says Maximize Market Research

Pune, April 10, 2023 (GLOBE NEWSWIRE) -- A global Healthcare business consulting and research firm, Maximize Market Research, has published a market intelligence and competitive landscape report on...
04. April 2023 17:15 ET | Quelle: The Rosen Law Firm PA

ROSEN, GLOBALLY RECOGNIZED INVESTOR COUNSEL, Encourages Phathom Pharmaceuticals, Inc. Investors to Inquire About Securities Class Action Investigation – PHAT

NEW YORK, April 04, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues its investigation of potential securities claims on behalf of shareholders of Phathom...
24. März 2023 07:30 ET | Quelle: Irwin Naturals

Irwin Naturals Cannabis Products Launch Nationwide in Canada

LOS ANGELES, March 24, 2023 (GLOBE NEWSWIRE) -- Irwin Naturals Inc. (CSE: IWIN) (OTC: IWINF) (FRA: 97X) (“Irwin” or the “Company”), is proud to announce the release of Irwin Naturals Cannabis’ new...
08. März 2023 07:00 ET | Quelle: ONL Therapeutics

ONL Therapeutics Closes First Tranche of $15 Million Series C Financing to Advance Lead Compound into Phase 2 Clinical Trial

ANN ARBOR, Mich., March 08, 2023 (GLOBE NEWSWIRE) -- ONL Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal...
14. Februar 2023 08:01 ET | Quelle: Corporation Geekco Technologies

Geekco annonce la conclusion d’un nouveau partenariat

LAVAL, Québec, 14 févr. 2023 (GLOBE NEWSWIRE) -- Corporation Geekco Technologies – (la « Société » ou « Geekco ») (TSX-V: GKO; OTCQB: GKOTF), a conclu un nouveau partenariat avec la chaîne...

Vorherige Seite

Nächste Seite